Message from the Director


On March 24,1882 Robert Koch announced to the world his discovery of the causative agent of tuberculosis. More than 50 years passed before the first effective drug – streptomycin – was discovered for this disease.  Over the next 25 years a number of additional drugs were discovered, forming the basis of our current TB drug regimen. Using these drugs requires 6 months of treatment for drug-sensitive TB and up to several years for multiple drug-resistant (MDR) or extensively drug resistant (XDR) TB. It has now been over 40 years since the introduction of the last drug developed primarily for use in TB – rifampin. Why? Read More..

About Us


The Institute for Tuberculosis Research (ITR), located at the University of Illinois at Chicago, is a drug discovery research facility working on the development of new drugs to combat an old, but still evolving global public health threat. The ITR is unique in that it brings an industrial model of drug discovery into an academic environment. In Chicago we have assembled all of the necessary components - medicinal chemistry, natural products chemistry, microbiology, drug metabolism, pharmacokinetics and toxicology – under one roof to maximize efficiency and communication. In addition to in-house discovery projects, we also collaborate with many public and private sector institutions around the world to facilitate their efforts towards the same goal.       Read More..

JavaScript is disabled!
To display this content, you need a JavaScript capable browser.





Our Mission

To discover and develop new effective, low-cost therapeutics for the treatment of tuberculosis. See an example of what drives this mission.

TB Facts

There were 9.27 million new TB cases in 2007, of which 80% were in just 22 countries. Per capita, the global TB incidence rate is falling, but the rate of decline is very slow - less than 1%.
Free Joomla 1.5 Templates by JoomlaShine.com